This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Clinicopathological significance of maspin and Kail expressions in carcinogenesis and progression of gastric cancer
Meng-Chun Wang, Yan-Min Yang, Xiao-Han Li, Fang Dong, Yan Li
Meng-Chun Wang, Yan-Min Yang, Yan Li, Department of Gastroenterology, Second Affiliated Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Xiao-Han Li, Fang Dong, Department of Pathology, Second Affiliated Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Correspondence to: Meng-Chun Wang, Department of Gastroenterology, Second Affiliated Hospital of China Medical University, Shenyang 110004, Liaoning Province China. firstname.lastname@example.org
Received: June 24, 2004 Revised: July 9, 2004 Accepted: August 5, 2004 Published online: October 15, 2004
AIM: To investigate the expressions of maspin and Kai1 in gastric cancer and to explore their roles in tumorigenesis and progression of gastric cancer.
METHODS: Normal gastric mucosa (n = 182), gastric dysplasia (n = 69), and gastric cancer (n = 113) were detected for maspin and Kai1 expressions by immunohistochemical methods. The expressions were compared with clinicopathological parameters of the tumor. Relationship between maspin and Kai1 expressions was analyzed as well.
RESULTS: The positive rates of maspin expression were 79.8% (145/182), 75.4% (52/69), and 50.4% (57/113) in normal gastric mucosa, gastric dysplasia, and gastric cancer, while those of Kai1 expression were 81.9% (149/182), 65.2% (49/69), and 58.4% (66/113) in corresponding tissues, respectively. The gastric normal mucosa and dysplasia more frequently expressed maspin than primary gastric cancer did, (P <0.01), while the normal mucosa showed more frequent expression of Kai1 than dysplasia and primary cancer did (P <0.01). Maspin expression significantly related to invasive depth (P = 0.003<0.01), metastasis (P = 0.027<0.05), Lauren's (P = 0.015<0.05) and histological classification (P = 0.024<0.05), but not to tumor size, Borrmann's classification, growth pattern and TNM staging (P >0.05). Kai1 expression significantly related to invasive depth (P = 0.043<0.05), metastasis (P = 0.005<0.01), growth pattern (P = 0.034<0.05), Lauren's classification (P = 0.000<0.01) and histological classification (P = 0.004<0.01), but not to tumor size, Borrmann's classification and TNM staging (P >0.05). Maspin expression was significantly consistent with Kail expression in primary gastric cancer (P = 0.008<0.05).
CONCLUSION: Down-regulated expressions of maspin and Kai1 play an important role in gastric carcinogenesis. They may have inhibitory effects on invasion and metastasis of gastric cancer. Abnormal expressions of maspin and Kai1 might be an objective indicator for pathobiological behaviors of gastric cancer.
Key Words: N/A
Citation: Wang MC, Yang YM, Li XH, Dong F, Li Y. Clinicopathological significance of maspin and Kail expressions in carcinogenesis and progression of gastric cancer. Shijie Huaren Xiaohua Zazhi 2004; 12(10): 2283-2286
Maass N, Hojo T, Zhang M, Sager R, Jonat W, Nagasaki K. Maspin--a novel protease inhibitor with tumor-suppressing activity in breast cancer.Acta Oncol. 2000;39:931-934.
Uzawa K, Ono K, Suzuki H, Tanaka C, Yakushiji T, Yamamoto N, Yokoe H, Tanzawa H. High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis.Clin Cancer Res. 2002;8:828-835.
Yang L, Kuang LG, Zheng HC, Li JY, Wu DY, Zhang SM, Xin Y. PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma.World J Gastroenterol. 2003;9:35-39.
Maass N, Biallek M, Rösel F, Schem C, Ohike N, Zhang M, Jonat W, Nagasaki K. Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer.Biochem Biophys Res Commun. 2002;297:125-128.
Spring P, Nakashima T, Frederick M, Henderson Y, Clayman G. Identification and cDNA cloning of headpin, a novel differentially expressed serpin that maps to chromosome 18q.Biochem Biophys Res Commun. 1999;264:299-304.
Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H, Domann FE. Role for DNA methylation in the control of cell type specific maspin expression.Nat Genet. 2002;31:175-179.
Primeau M, Gagnon J, Momparler RL. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells.Int J Cancer. 2003;103:177-184.
Maass N, Teffner M, Rösel F, Pawaresch R, Jonat W, Nagasaki K, Rudolph P. Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast.J Pathol. 2001;195:321-326.
Maass N, Hojo T, Rösel F, Ikeda T, Jonat W, Nagasaki K. Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis.Clin Biochem. 2001;34:303-307.
Machtens S, Serth J, Bokemeyer C, Bathke W, Minssen A, Kollmannsberger C, Hartmann J, Knüchel R, Kondo M, Jonas U. Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features.Int J Cancer. 2001;95:337-342.
Reddy KB, McGowen R, Schuger L, Visscher D, Sheng S. Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model.Oncogene. 2001;20:6538-6543.
Yasumatsu R, Nakashima T, Hirakawa N, Kumamoto Y, Kuratomi Y, Tomita K, Komiyama S. Maspin expression in stage I and II oral tongue squamous cell carcinoma.Head Neck. 2001;23:962-966.
Domann FE, Rice JC, Hendrix MJ, Futscher BW. Epigenetic silencing of maspin gene expression in human breast cancers.Int J Cancer. 2000;85:805-810.
Biliran H Jr, Sheng S. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.Cancer Res. 2001;61:8676-8682.
Blacque OE, Worrall DM. Evidence for a direct interaction between the tumor suppressor serpin, maspin, and types I and III collagen.J Biol Chem. 2002;277:10783-10788.
Seftor RE, Seftor EA, Sheng S, Pemberton PA, Sager R, Hendrix MJ. maspin suppresses the invasive phenotype of human breast carcinoma.Cancer Res. 1998;58:5681-5685.
Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor.Nat Med. 2000;6:196-199.
Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S. Maspin sensitizes breast carcinoma cells to induced apoptosis.Oncogene. 2002;21:4089-4098.
Guo XZ, Friess H, Shao XD, Liu MP, Xia YT, Xu JH, Buchler MW. KAI1 gene is differently expressed in papillary and pancreatic cancer: influence on metastasis.World J Gastroenterol. 2000;6:866-871.
Si SH, Yang JM, Peng ZH, Luo YH, Zhou P. Effects of KAI1 gene on growth and invasion of human hepatocellular carcinoma MHCC97-H cells.World J Gastroenterol. 2004;10:2019-2023.
Wu DH, Liu L, Chen LH, Ding YQ. KAI1 gene expression in colonic carcinoma and its clinical significances.World J Gastroenterol. 2004;10:2245-2249.
Wu ZL, Wu ZH, Guo X. [Study on the expression of the metastasis suppressor gene KAI1 in laryngeal squamous cell carcinoma].Zhonghua Erbiyanhouke Zazhi. 2003;38:413-416.
Marreiros A, Czolij R, Yardley G, Crossley M, Jackson P. Identification of regulatory regions within the KAI1 promoter: a role for binding of AP1, AP2 and p53.Gene. 2003;302:155-164.
Jee B, Jin K, Hahn JH, Song HG, Lee H. Metastasis-suppressor KAI1/CD82 induces homotypic aggregation of human prostate cancer cells through Src-dependent pathway.Exp Mol Med. 2003;35:30-37.
Hashida H, Takabayashi A, Tokuhara T, Taki T, Kondo K, Kohno N, Yamaoka Y, Miyake M. Integrin alpha3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82.Int J Cancer. 2002;97:518-525.